Peptide drug discovery and development for oral NCE therapeutics
Protagonist Therapeutics discovers and develops peptide-based drug candidates engineered for oral stability. Its stack pairs lab and chemistry tools (ChemDraw, SciFinder, LC-MS/MS, LIMS) with pharmacometrics software (Phoenix WinNonlin, NONMEM) and GPT, Gemini and MCP. A Head of AI search signals AI moving into discovery. Senior and director-heavy hiring in research, plus a Toxicology Director role, points to pipeline molecules advancing from Phase 1 through Phase 3.
Notable leadership hires: Toxicology Director, Head of AI
Protagonist Therapeutics is a publicly traded biopharmaceutical company (Nasdaq: PTGX) headquartered in Newark, California, founded in 2006. It runs a proprietary platform for designing peptide new chemical entities de novo, tuning potency and selectivity and applying chemical modifications for oral delivery. The company targets disease areas with significant unmet medical need. It employs 51–200 people and hires in the United States across research, engineering, operations, manufacturing and pharmacology.
Scientific tools include ChemDraw, SciFinder, Spotfire, LIMS, HPLC-MS, GraphPad Prism, Phoenix WinNonlin and NONMEM, alongside Python, MATLAB, AWS, Azure, GCP, Smartsheet and IT tools like Intune and Freshservice.
Yes. It is recruiting a Head of AI, and its stack already includes GPT, Gemini and MCP, suggesting AI is being formalized as a leadership function. Overall hiring velocity is decelerating.
Protagonist Therapeutics is headquartered in Newark, California, and its current hiring is focused in the United States.
Other companies in the same industry, closest in size
Protagonist Therapeutics's technology stack, projects, and hiring signals are inferred from public hiring and company data — career pages, public listings, and company web presence — then clustered and de-duplicated. Figures are estimates that refresh over time. Read our full methodology →
This is not an official vendor or customer list. It is a technology-adoption signal inferred from public data, intended for B2B research.